Currently, the majority of ovarian cancers – upwards of 75 percent – are of the subtype “high grade serous carcinoma,” which is the type being treated in this phase 2 study.
Economic Analysis of Early vs Delayed Therapy in Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Muscosal Melanoma
Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)
The recently launched Centre for Health Innovation, aims to connect researchers from across multiple disciplines to tackle the most pressing human health challenges. A critical part of the centre will be a new home for the CCTG Tumour Tissue Data Repository and includes a large-scale expansion of its histopathology and biobanking resources.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)
The Canadian Cancer Trials Group (CCTG) Operations and Statistics Centre will receive full funding of $19,457,683 through The Major Science Initiatives (MSI) Fund. Minister of Innovation, Science and Industry, François-Philippe Champagne announced the award at Queen’s University as part of the 19 successful research infrastructure projects receiving $628 million from the Canada Foundation for Innovation (CFI). The funding supports state-of-the-art facilities of national importance to drive innovative research in Canada.
“The continuing investment from CFI will ensure CCTG continues to conduct research of the exceptional caliber and competitive with the best in the world,” acknowledges Dr Janet Dancey, CCTG Director. “The award acknowledges CCTG as a national resource that is used by leading Canadian researchers who are internationally recognized for their work.”
The MSI review recognized that CCTG central operations at Queen’s as a unique Canadian research facility. Also noted were the impressive Canadian network, and success in advancing the full spectrum of cancer clinical trials for researchers and patients across Canada and the world.
“The CCTG has received continuous investment through the MSI program, marking its critical importance in the Canadian research landscape and Queen’s leadership in this area,” says Dr. Nancy Ross, Vice-Principal (Research). "Through clinical trials and the work of the CCTG, we are defining new standards of care, diagnostic tests, and therapies, having a positive impact on cancer patients worldwide.”
The CFI MSI Funding will support the CCTG trials operations, assures development of the highly innovative personalized cancer therapies, expand its operations and data platforms to support innovative clinical trials and related research.
A new CCTG national study has received funding from the Social Sciences and Humanities Research Council and Genome Canada to explore the ethical questions raised with emerging cancer technologies like CAR-T cell therapy.
Three CCTG trials were recently awarded nearly $7.5M from the Canadian Institutes of Health Research (CIHR) 2022 Spring Project Grant competition.
The CCTG New Investigator Clinical Trials Course is fast approaching and has already reached the maximum registration. The course will be held August 3 – 5, 2022 in Kingston, Ontario to provide and facilitate investigator education and training designed to educate new investigators from across the country about the essentials of clinical trial conduct in the Canadian research environment.
It was recently announced that ExCELLirate Canada has successfully been granted a Research Infrastructure award of $4,159,049 by the Ontario Research Fund for the Innovation Fund Project Grant "ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation".
CCTG trials that were featured at the American Society of Clinical Oncology General Meeting 2022 June 3-7, 2022 – McCormick Place, Chicago
The findings of the CCTG MA32 trial were published recently in the Journal of the American Me
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)
PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)
Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
Phase II Pre-operative Platform Trial in Surgically Resectable NSCLC
De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)
Adjuvant Treatment Guided by Response Post Neoadjuvant Therapy for Stage III Melanoma
NET RETREAT: 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET
Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy
The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS
A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC
STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Androgen Suppression combined with Elective Nodal and a Dose Escalated Boost. Stereotactic Body Radiation Therapy vs Brachytherapy Boost (ASCENDE-SBRT)
Late Recurrence Substudy of A Phase III Randomized Trial of Metformin vs Placebo on Recurrence and Surivival in Early-Stage Breast Cancer
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.
CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.
“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
Nature Communications 13: 5020, 2022Renouf DJ;Loree JM;Knox JJ;Topham JT;Kavan P;Jonker D;Welch S;Couture F;Lemay F;Tehfe M;Harb M;Aucoin N;Ko YJ;Tang PA;Ramjeesingh R;Meyers BM;Kim CA;Du P;Jia S;Schaeffer DF;Gill S;Tu D;O'Callaghan CJ;
J Clin Oncol : JCO, 2022Topham JT;O'Callaghan CJ;Feilotter H;Kennecke HF;Lee YS;Li W;Banks KC;Quinn K;Renouf DJ;Jonker DJ;Tu D;Chen EX;Loree JM;
J Clin Oncol : JCO, 2022Morschhauser F;Nastoupil L;Feugier P;Schiano de Colella J;Tilly H;Palomba ML;Bachy E;Fruchart C;Libby EN;Casasnovas RO;Flinn IW;Haioun C;Maisonneuve H;Ysebaert L;Bartlett NL;Bouabdallah K;Brice P;Ribrag V;Le Gouill S;Daguindau N;Guidez S;Pica GM;Garcia-Sancho AM;Lopez-Guillermo A;Larouche JF;Ando K;Gomes da Silva M;Andre M;Kalung W;Sehn LH;Izutsu K;Cartron G;Gkasiamis A;Crowe R;Xerri L;Fowler NH;Salles G;
, 2022Wang X;Kozono D;Watt C;Landrenau R;Wigle D;Port J;Jones DR;Conti M;Ashrafi AS;Keenan R;Bauer T;Kohman LJ;Stinchcombe T;Vokes E;
Clin Oncol , 2022Parker CC;Clarke NW;Catton C;Kynaston H;Cook A;Cross W;Davidson C;Goldstein C;Logue J;Maniatis C;Petersen PM;Neville P;Payne H;Persad R;Pugh C;Stirling A;Saad F;Parulekar WR;Parmar MKB;Sydes MR;
The Oncol 27: e286 - e293, 2022Wells JC;Sidhu A;Ding K;Smoragiewicz M;Heng DYC;Shepherd FA;Ellis PM;Bradbury PA;Jonker DJ;Siu LL;Gelmon KA;Karapetis C;Shapiro J;Nott L;O'Callaghan CJ;Parulekar WR;Seymour L;Monzon JG;
J Immunother Cancer 10: e004849 - e004856, 2022Ramon-Patino JL;Schmid S;Lau S;Seymour L;Gaudreau PO;Li JJN;Bradbury PA;Calvo E;